Comparative Pharmacology
Head-to-head clinical analysis: DROPERIDOL versus ETRAFON 2 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROPERIDOL versus ETRAFON 2 25.
DROPERIDOL vs ETRAFON 2-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droperidol is a butyrophenone antipsychotic that acts primarily as a dopamine D2 receptor antagonist. It also exhibits antiemetic effects via blockade of dopamine D2 receptors in the chemoreceptor trigger zone. Additionally, it has alpha-adrenergic blocking properties and can prolong the QT interval by blocking cardiac potassium channels (hERG).
Combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks postsynaptic dopamine D2 receptors in the mesolimbic system, also antagonizes alpha-adrenergic, histaminergic, and muscarinic receptors. Amitriptyline inhibits reuptake of serotonin and norepinephrine at the presynaptic neuronal membrane, enhancing serotonergic and noradrenergic neurotransmission.
2.5-10 mg IV/IM every 3-4 hours as needed for nausea and vomiting; for agitation or psychosis in perioperative settings: 0.625-1.25 mg IV/IM, may repeat every 6 hours.
One tablet (2 mg perphenazine, 25 mg amitriptyline) orally three or four times daily. Maintenance: 2-4 tablets daily.
None Documented
None Documented
Clinical Note
moderateDroperidol + Norfloxacin
"Droperidol may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDroperidol + Ibandronate
"Droperidol may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateDroperidol + Indapamide
"Droperidol may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateDroperidol + Methylphenidate
"The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate."
Terminal elimination half-life: 2.3 hours (range 1.5–4.7 hours). Clinical context: Short half-life allows rapid titration but requires repeated dosing or continuous infusion for sustained effect; accumulation with hepatic impairment.
Perphenazine: 8-12 hours (terminal); amitriptyline: 15-24 hours (terminal), with nortriptyline active metabolite half-life 18-44 hours. Steady-state achieved in 4-7 days.
Renal (75% as metabolites, <1% unchanged); fecal (22%); biliary excretion contributes to enterohepatic circulation.
Renal: approximately 25-50% as metabolites and unchanged drug; biliary/fecal: 10-25% as metabolites; the remainder is extensively metabolized via hepatic pathways.
Category A/B
Category C
Antipsychotic
Antipsychotic/Antidepressant Combination